A Gamma Variant RBD-based aluminum hydroxide adjuvanted vaccine called ARVAC CG was selected for a first in human clinical trial. Healthy male and female participants (18-55 years old) with a complete COVID-19-primary vaccine scheme were assigned to
CONCLUSION: In a relatively young and healthy Brazilian population, two doses of BNT162b2 provided protection against symptomatic Omicron infection. However, this protection waned significantly over time, underscoring the need for boosting with
CONCLUSION: Allergic reactions coded as IMEs during commercial air travel are uncommon, occurring at an incidence around 10-100 times lower than that reported for accidental allergic reactions to food occurring in the community. Despite increasing
Little is known about the CD8^(+) T cell functionality in the coronavirus disease 2019 (COVID-19). Therefore, we examined twenty-five hospitalized COVID-19 patients with moderate (MD) or severe disease (SD) as well as seventeen SARS-CoV-2-unexposed
CONCLUSIONS: Longer TLKW to hospital arrival during COVID did not impact arrival-to-imaging, arrival-to-treatment times nor patient outcomes, even in patients at higher risk for stroke. Future studies should continue to assess the impact of COVID-19
CONCLUSION: Since there was no difference in clinical improvement between the use of 250 mg or 1000 mg methylprednisolone in patients with severe coronavirus disease 2019 infection, 1000 mg methylprednisolone was not required.
CONCLUSIONS: Knowing the diameters of maximum pulmonary artery and maximum ascending aorta and the maximum pulmonary artery-maximum ascending aorta ratio in hospitalized severe acute respiratory syndrome coronavirus 2-infected patients is a valuable
CONCLUSION: The male gender is more probable to be involved in the development of pneumothorax or pneumomediastinum in patients with SARS-CoV-2 pneumonia. The incidence of these events is low, and conservative treatment could provide a better outcome